CAJ | 학술논문

目的：探讨应用FOLFOX4方案化疗联合射频消融(RFA)治疗伴有门脉癌栓的局部晚期原发性肝癌的疗效。方法46例经临床确诊伴有门脉癌栓的局部晚期原发性肝癌患者随机分为两组,联合组(n=24)：此组患者先行RFA治疗,每4周治疗1次,共4个疗程,第1次RFA治疗后1周行FOLFOX4方案化疗,14 d为1个周期,共12个周期；单纯射频组(n=22)：此组患者单纯采用射频消融治疗,每4周治疗1次,共4个疗程。观察终点为病情进展。结果联合组患者治疗后1、2、3年无瘤生存率分别为75.2%、51.0%和36.1%,射频组患者治疗后1、2、3年无瘤生存率分别为60.0%、31.2%和15.7%,差异有统计学意义(P=0.024)。结论对于肿瘤直径为3~5 cm的多个病灶结节合并门脉癌栓的原发性肝癌患者, FOLFOX4方案化疗联合射频消融治疗的疗效优于单纯射频消融。
목적：탐토응용FOLFOX4방안화료연합사빈소융(RFA)치료반유문맥암전적국부만기원발성간암적료효。방법46례경림상학진반유문맥암전적국부만기원발성간암환자수궤분위량조,연합조(n=24)：차조환자선행RFA치료,매4주치료1차,공4개료정,제1차RFA치료후1주행FOLFOX4방안화료,14 d위1개주기,공12개주기；단순사빈조(n=22)：차조환자단순채용사빈소융치료,매4주치료1차,공4개료정。관찰종점위병정진전。결과연합조환자치료후1、2、3년무류생존솔분별위75.2%、51.0%화36.1%,사빈조환자치료후1、2、3년무류생존솔분별위60.0%、31.2%화15.7%,차이유통계학의의(P=0.024)。결론대우종류직경위3~5 cm적다개병조결절합병문맥암전적원발성간암환자, FOLFOX4방안화료연합사빈소융치료적료효우우단순사빈소융。
Objective To compare the effect of chemotherapy of FOLFOX 4 combined with radiofrequency ablation (RFA) and radiofrequency ablation alone for the treatment of 3~5 cm hepatocellular carcinoma (HCC) with portal vein tumor thrombus.Methods Choosing 46 cases of clinically diagnosed locally advanced hepatocellular carcinoma with portal vein tumor thrombus patients and randomly dividing them into two groups, FOLFOX 4 combined with RFA group (n=24): first with RFA therapy, once every 4 weeks, a total of 4 sessions, first week after RFA treatment with FOLFOX 4 chemotherapy, 14 days for a cycle, a total of 12 cycles; RFA alone group(n =22): patients treatment with RFA alone, once every 4 weeks, a total of 4 sessions. Observed disease progression.Results Disease free survival of FOLFOX 4 combined with RFA group after 1 year, 2 year, 3 year were 75.2%, 51.0%, and 36.1%, and RFA alone group were 60.0%, 31.2% and 15.7%. The differences between the two groups were statistically significant(P=0.024).Conclusion Chemotherapy of FOLFOX 4 plus RFA are better than RFA alone for the treatment of 3~5cm hepatocellular carcinoma with portal vein tumor thrombus.